Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON7 bevacizumab plus carboplatin/paclitaxel in newly diagnosed epithelial ovarian cancer
2005-003929-22Phase 3Completed
- Sponsor
- Medical Research Council
- Start
- Nov 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Medical Research Council. Primary endpoint: Progression-free survival. Started Nov 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2005-003929-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003929-22.